Are you in VIC? If not, please change below.

In your state, you are required to confirm you wish to access this information. Please enter 'QLD' or 'WA' in the field below to continue.

No thanks

Royal Bank of Scotland Class Action heads to court

Outside a courtroom | Shine Lawyers

On 15 June 2017, Shine Lawyers visited the Federal Court of Sydney to advance a class action against the Royal Bank of Scotland (RBS) on behalf of more than 200 customers who suffered loss following inappropriate investment advice. With the class action set down for trial in March 2018, the Federal Court will order that notices be sent to all affected customers to ensure they understand their entitlements to seek redress for the loss they’ve suffered.

What is the RBS class action about?

The action against the Royal Bank of Scotland will allege that RBS financial products were sold to clients of Penrith-based Navra Financial Services (Navra) between February 2008 and March 2011, and that these products were inappropriate for their purposes and were only suitable for speculative investors. Shine Lawyers is alleging that RBS took no steps to determine whether or not these products were suitable for the clients’ investment purposes.

Shine Lawyers Class Actions Principal Vicky Antzoulatos said the action would see RBS facing millions of dollars in claims for breach of contract, unconscionable conduct and liability as a linked credit provider to Navra.

Everyday Australians affected

“Our clients are mums and dads and retirees who lost their life savings after investing in a product that was totally inappropriate for their needs,” said Ms Antzoulatos. “The hearing will see them finally granted their day in court and orders will be made for the preparation of the case for trial,” she said.

“Some customers were advised to mortgage their homes to raise funds to purchase RBS claim warrants the value of which would eventually be wiped out.”

Ms Antzoulatos said the firm believes that in most cases, RBS did little or nothing to verify the clients’ ability to repay the margin loans, instead preferring to engage in ‘asset lending’.

“No amount of money will ever truly compensate our clients for the effect this has had on their lives but compensation will provide them some vindication and will allow them to start to put their lives back on track. We are hopeful that RBS will work with those customers impacted to resolve this matter without the need for a lengthy court process.”

woman-and-lawyer-sign-document

Shine Lawyers’ Class Actions Department

Visit here for more information on the RBS Class Action, or get in touch with a member of Shine Lawyers’ Class Actions Practice if you feel you should be part of the action.

Written by Shine Lawyers on . Last modified: March 13, 2018.

Join the discussion

Share this article:

There are 0 comments. Be the first!

Audi, Skoda and Volkswagen Potential Class Action

Shine Lawyers is examining claims against Audi, Skoda and Volkswagen following US class actions, alleging that several vehicles have a defective timing chain, which can cause catastrophic engine failure. Volkswagen, Skoda and Audi vehicles that contain 1.8L and 2.0L TSI and TFSI EA888 engines manufactured between 2008 and 2012 are the vehicles that have been […]

Read more

Shine lawyers warn Apple may face class action in Australia

After investigating the matter carefully we have formed the view at this stage that consumers would not benefit from the commencement of any proceedings against Apple in respect of this matter. We will continue to monitor the position and if the situation changes we will notify via our website. Class Actions against technology juggernaut Apple […]

Read more

TGA’s mesh ban welcomed but needs to go further

Mesh victims and participants in the Shine Lawyers Johnson & Johnson mesh class action have welcomed news that the Therapeutic Goods Administration (TGA) will ban the use of vaginal mesh implants for pelvic prolapse in Australia after finding that the risks outweigh the benefits. The TGA announced the decision following a review of clinical evidence […]

Read more